STSA — Satsuma Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $36.47m
- -$4.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.97 | ||
| Price to Tang. Book | 0.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -175.76% | ||
| Return on Equity | -104.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 4.38 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
Directors
- Heath Lukatch CHM (54)
- John Kollins PRE (57)
- Tom O'Neil CFO (55)
- Mic Iwashima VPR
- Detlef Albrecht OTH (59)
- Rob Janosky OTH
- Mutya Harsch DRC (46)
- Thomas Soloway DRC (53)
- Thomas King IND (65)
- Michael Riebe IND (59)
- Elisabeth Sandoval IND (59)
- Rajeev Shah IND (42)
- Ken Takanashi IND (57)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- June 21st, 2016
- Public Since
- September 13th, 2019
- No. of Shareholders
- 7
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 33,152,498
- Address
- 4819 EMPEROR BOULEVARD, SUITE 340, DURHAM, 27703
- Web
- https://www.satsumarx.com/
- Phone
- +1 4155050809
- Auditors
- KPMG LLP
Upcoming Events for STSA
Q3 2023 Satsuma Pharmaceuticals Inc Earnings Release
Similar to STSA
89bio
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Satsuma Pharmaceuticals share price?
As of Today at 19:19 UTC, shares in Satsuma Pharmaceuticals are trading at $1.10. This share price information is delayed by 15 minutes.
How has the Satsuma Pharmaceuticals share price performed this year?
Shares in Satsuma Pharmaceuticals last closed at $1.10 and the price had moved by -65.3% over the past 365 days. In terms of relative price strength the Satsuma Pharmaceuticals share price has underperformed the S&P500 Index by -68.51% over the past year.
What are the analyst and broker recommendations for Satsuma Pharmaceuticals?
The overall consensus recommendation for Satsuma Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Satsuma Pharmaceuticals dividend yield?
Satsuma Pharmaceuticals does not currently pay a dividend.
Does Satsuma Pharmaceuticals pay a dividend?
Satsuma Pharmaceuticals does not currently pay a dividend.
When does Satsuma Pharmaceuticals next pay dividends?
Satsuma Pharmaceuticals does not currently pay a dividend.
How do I buy Satsuma Pharmaceuticals shares?
To buy shares in Satsuma Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Satsuma Pharmaceuticals?
As of the previous close price of $1.10, shares in Satsuma Pharmaceuticals had a market capitalisation of $36.47m.
Where are Satsuma Pharmaceuticals shares listed?
Here are the trading details for Satsuma Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: STSA
What kind of share is Satsuma Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Satsuma Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Satsuma Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Satsuma Pharmaceuticals is $2.00. That is 81.82% above the last closing price of $1.10.
Analysts covering Satsuma Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.95 for the next financial year.
What is the trend in the Satsuma Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Satsuma Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +17.72%.
As of the last closing price of $1.10, shares in Satsuma Pharmaceuticals were trading -53.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Satsuma Pharmaceuticals PE Ratio?
The Satsuma Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals' management team is headed by:
- Heath Lukatch - CHM
- John Kollins - PRE
- Tom O'Neil - CFO
- Mic Iwashima - VPR
- Detlef Albrecht - OTH
- Rob Janosky - OTH
- Mutya Harsch - DRC
- Thomas Soloway - DRC
- Thomas King - IND
- Michael Riebe - IND
- Elisabeth Sandoval - IND
- Rajeev Shah - IND
- Ken Takanashi - IND